ArticleRadiation oncology (London, England)2019

Palliative radiotherapy to dominant symptomatic lesion in patients with hormone refractory prostate cancer (PRADO).

Jesper Carl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.